Limited cardiotoxicity after extensive thoracic surgery and intraoperative hyperthermic intrathoracic chemotherapy with doxorubicin and cisplatin

Annals of Surgical Oncology

Volumn 14, Issue 10, 2007, Pages 3019-3026

  De Bree, Eelco ^a   Van Ruth, Serge ^a   Schotborgh, Carl E ^b   Baas, Paul ^a   Zoetmulder, Frans A N ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Cardiotoxicity; Cisplatin; Doxorubicin; Intrapleural chemotherapy; Intrathoracic chemotherapy; Mesothelioma

Indexed keywords

CISPLATIN; DOXORUBICIN; TROPONIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CHEMOSURGERY; CLINICAL ARTICLE; CLINICAL EXAMINATION; CORRELATION ANALYSIS; CYTOREDUCTIVE SURGERY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG FATALITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY MONITORING; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTHERMIC THERAPY; LUNG EMBOLISM; MALE; PATIENT MONITORING; PERICARDIECTOMY; PERICARDIUM; PEROPERATIVE CARE; PLEURA MESOTHELIOMA; PREDICTION; PROTEIN SECRETION; RADIOISOTOPE VENTRICULOGRAPHY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THORAX SURGERY; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATRIAL FIBRILLATION; CARDIOMYOPATHIES; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CISPLATIN; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM INVASIVENESS; PERICARDIECTOMY; PLEURAL NEOPLASMS; STROKE VOLUME; THORACOTOMY; TROPONIN T; VENTRICULAR DYSFUNCTION, LEFT;

EID: 34648846848     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9508-3     Document Type: Article

References (46)

1. Tan C, Sedrakyan A, Browne J, et al. The evidence of the effectiveness of management for malignant pleural effusion: a systemic review. Eur J Cardiothorac Surg 2006; 29:829-38
2. Witkamp AJ, de Bree E, van Goethem R, et al. Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev 2001; 27:365-74
3. de Bree E, van Ruth S, Baas P, et al. Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma. Chest 2002; 121:480-7
4. van Ruth S, Baas P, Haas RLM, et al. Cytoreductive surgery combined with intraoperative hyperthermic intrathoracic chemotherapy for stage I malignant pleural mesothelioma. Ann Surg Oncol 2003; 10:176-82
5. Monneuse O, Beaujard AC, Guibert B, et al. Long-term results of intrathoracic chemohyperthermia (ITCH) for the treatment of pleural malignancies. Br J Cancer 2003; 88:1839-43
6. Matsuzaki Y, Shibata K, Yoshioka M, et al. Intrapleural perfusion hyperthermo-chemotherapy for malignant pleural dissemination and effusion. Ann Thorac Surg 1995; 59:127-31
7. Yellin A, Simansky DA, Paley M, et al. Hyperthermic pleural perfusion with cisplatin. Early clinical experience. Cancer 2001; 92:2197-203
8. Ratto GB, Civalleri D, Espositi M, et al. Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: a feasibility and pharmacokinetic study. J Thorac Cardiovasc Surg 1999; 117:759-65
9. Rafaely Y, Simansky DA, Paley M, et al. Resection and perfusion thermochemotherapy: a new approach for the treatment of thymic malignancies with pleural spread. Ann Thorac Surg 2001; 72:366-70
10. Shigemura N, Akashi A, Nakagiri T, et al. Pleural perfusion thermo-chemotherapy under VATS: a new less invasive modality for advanced lung cancer with pleural spread. Ann Thorac Surg 2004; 77:1016-22
11. Fujimara T, Yonemura Y, Nojima N, et al. Intrathoracic hyperthermochemotherapeutic perfusion for intrathoracic malignancies in gastric cancer. Hepatogastroenterology 1995; 42:878-84
12. Richards WG, Zellos L, Bueno R, et al. Phase I to II study of pleurectomy / decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol 2006; 24:1561-7
13. van Ruth S, van Tellingen O, Korse CM, et al. Pharmacokinetics of doxorubicin and cisplatin used in intraoperative hyperthermic intrathoracic chemotherapy after cytoreductive surgery for malignant pleural mesothelioma and pleural thymoma. Anticancer Drugs 2003; 14:57-65
14. Elisson LO, Bjorkman S. Congestive heart failure in rabbits after a single intrapleural administration of a low dose of doxorubicin or epirubicin. Pharmacol Toxicol 1988; 62:84-9
15. Schimmel KJM, Richel DJ, van den Brink RBA, et al. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 2004;30:181-91
16. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91:710-7
17. Danesi R, Fogli S, Gennari A, et al. Pharmacokinetic - pharmacodynamic relationship of the anthracycline anticancer drugs. Clin Pharmacokinet 2002; 41:431-44
18. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents. Incidence, treatment, and prevention. Drug Safety 2000; 22:304-9
19. Swain M, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin. Cancer 2003; 97:2869-79
20. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998;25 (suppl 10):72-85
21. Icli F, Karaoguz H, Dincol D, et al. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer 1993; 15:587-93
22. Doll Dc, List AF, Greco FA, et al. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med 1986; 105:48-51
23. Meinardi MT, Gietema JA, van der Graaf WT, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000; 18:1725-32
24. Lu P. Monitoring cardiac function in patients receiving doxorubicin. Semin Nucl Med 2005; 35:197-201
25. Ng R, Better N, Green MD. Anticancer agents and cardiotoxicity. Semin Oncol 2006; 33:2-14
26. Herman EH, Zhang J, Lipshultz S, et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 1999; 17:2237-43
27. Cardinale D, Sandri M, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109:2749-54
28. Lipshultz SE, Rifai N, Sallan SE, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997; 96:2641-8
29. Sandri MT, Cardinale D, Zorzino L, et al. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem 2003; 49:248-52
30. Kremer LC, Bastiaansen BA, Offringa M, et al. Troponin T in the first 24 hours after the administration of chemotherapy and the detection of myocardial damage in children. Eur J Cancer 2002; 38:686-9
31. Koseoglu V, Berberoglou S, Karademir S, et al. Cardiac troponin I: is it a marker to detect cardiotoxicity in children treated with doxorubicin. Turk J Pediatr 2005; 47:17-22
32. Mathew P, Suarez W, Kip K, et al. Is there a role for serum cardiac troponin I as a marker for myocardial dysfunction in pediatric patients receiving anthracycline-based therapy? A pilot study. Cancer Invest 2001; 19:352-9
33. Auner HW, Tinchon C, Linkesch W, et al. Prolonged monitoring of troponin T for the detection of anthracycline Cardiotoxicity in adults with haematological malignancies. Ann Hematol 2003; 82:218-22
34. Kismet E, Varan A, Ayabakan C, et al. Serum troponin T levels and echocardiographic evaluation in children treated with doxorubicin. Pediatr Blood Cancer 2004; 42:220-4
35. Urano M, Kuroda M, Nishimura Y. For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthermia 1999; 15:79-107
36. Urano M, Begley J, Reynolds R. Interaction between adriamycin cytotoxicity and hyperthermia: growth-phase-dependent thermal sensitization. Int J Hyperthermia 1994; 10:817-26
37. Goldstein LS, Dewhirst MW, Repacholi M, Kheifets L. Summary, conclusions and recommendations: adverse temperature levels in the human body. Int J Hyperthermia 2003; 19:373-84
38. Dewhirst MW, Viglianti BL, Lora-Michelis M, et al. Basic principles of thermal dosimetry and thermal thresholds for tissue damage from hyperthermia. Int J Hyperthermia 2003; 19:267-94
39. Nagaoka S, Kawasaki S, Sasaki K, et al. Intracellular uptake, retention and cytotoxic effect of adriamycin combined with hyperthermia in vitro. Jpn J Cancer Res 1986; 77:205-11
40. Los G, Sminia P, Wondergem J, et al. Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur J Cancer 1991; 27:472-7
41. Sesan S. Indications and limitations of radiotherapy in malignant pleural mesothelioma. Curr Opinion Oncol 2003; 15:144-7
42. Boutin C, Rey F, Viallat J-R. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 1995; 108:754-8
43. Cuzick J, Stewart H, Rutquist L, et al. Cause specific mortality in long term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 1994; 12:447-53
44. Marks L, Yu X, Prosnitz RG, et al. The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys 2005; 63:214-23
45. Ozols RF, Locker GY, Doroshow JH, et al. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res 1979; 39:3209-14
46. van der Vaart PJM, van der Vange N, Zoetmulder FAN, et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: Pharmokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 1998; 34:148-54